Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MLSN1 CRISPR/Cas9 KO Plasmid (h): sc-406812
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MLSN1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MLSN1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MLSN1 Antibody (F-3): sc-515228
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MLSN1 CRISPR/Cas9 KO Plasmid (h) | sc-406812 | 20 µg | $397.00 |
Overview
TRPM1 encodes the melastatin subfamily cation channel MLSN1, a Ca2+-permeable TRP channel that contributes to membrane excitability and intracellular calcium signaling. In retinal ON-bipolar cells, TRPM1 functions as a key effector downstream of metabotropic glutamate receptor 6 (mGluR6) in phototransduction, coupling synaptic glutamatergic input to depolarizing responses. Beyond the retina, TRPM1-linked calcium flux can influence signaling programs that intersect with second-messenger pathways and transcriptional regulation. Genetic disruption or dysregulation of TRPM1 has been associated with visual signaling defects and is also studied in pigmentation-related biology, supporting its relevance to neurobiology and melanocyte-associated processes.
MLSN1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TRPM1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TRPM1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TRPM1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MLSN1 protein expression.
This CRISPR knockout system enables efficient generation of TRPM1-deficient cell models for investigation of MLSN1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TRPM1 exon(s) critical for MLSN1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TRPM1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MLSN1 CRISPR/Cas9 KO Plasmid (h) and MLSN1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TRPM1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MLSN1 HDR Plasmid (h) and MLSN1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TRPM1 homology arms to support homology-directed repair at defined TRPM1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.